Novartis
Novartis. Search. Global | en. Menu. Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Products - Novartis
Products. Below is a list of the treatments we currently offer via our US and International units. Please note: Not all treatments are available in all countries. All Products. Show More Links. Active Ingredients. A-Z. Showing 97 results.
Career Search - Novartis
Site. Date Posted. Rheumatology Territory Account Specialist – Houston West – Remote Regular (Sales), Full time. Innovative Medicines. USA +Alternative Locations. Field Sales (USA) Nov 09, 2024. Senior Process Expert (m/f/d) - Temporary Befristet (Befristet), Full …
About - Novartis
About. Learn more about Novartis and explore our core therapeutic areas and technology platforms. Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.
Careers - Novartis
Careers | Novartis. Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Information for patients and their ...
Reclast helps reduce the chance of having a hip or spinal fracture (break). Increase bone mass in men with osteoporosis. Treat or prevent osteoporosis in either men or women who will be taking corticosteroid medicines for at least one year. Treat certain men and women who have Paget’s disease of the bone.
11 DESCRIPTION. ENTRESTO (sacubitril and valsartan) is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker. ENTRESTO contains a complex comprised of anionic forms of sacubitril and valsartan, sodium cations, and water molecules in the molar ratio of 1:1:3:2.5, respectively.
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to ...
Dec 22, 2021 · Ad hoc announcement pursuant to Art. 53 LR. With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction 1; Leqvio provides effective and sustained LDL-C reduction of up to 52% vs. placebo for certain people with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin therapy 2,3
Novartis Pluvicto™ approved by FDA as first targeted radioligand ...
Mar 23, 2022 · Ad hoc announcement pursuant to Art. 53 LR . FDA also approved complementary diagnostic imaging agent, Locametz ®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions 2; Metastatic prostate cancer has a 5-year survival rate of less than 30% 3; mCRPC patients who progress on multiple lines of therapy have limited treatment options
Research and development - Novartis
Research and development. We are an innovative medicines company with research and development at our core. Our R&D engine powers an industry-leading pipeline focused on delivering transformative medicines to fight disease, restore possibility and help people live life on their own terms. Researchers in Biomedical Research work across several ...